Sudeep Pharma Limited (NSE:SUDEEPPHRM)

Market Cap	135.52B
Revenue (ttm)	6.76B +31.8%
Net Income	1.83B +33.7%
EPS	16.21 +29.2%
Shares Out	112.95M
PE Ratio	74.01
Forward PE	67.36
Dividend	1.50 (0.12%)
Ex-Dividend Date	Jul 23, 2026

Volume	205,621
Open	1,222.20
Previous Close	1,205.80
Day's Range	1,171.10 - 1,237.30
52-Week Range	524.05 - 1,378.00
Beta	n/a
Analysts	Sell
Price Target	777.50 (-35.48%)
Est. Earnings	Nov 5, 2026

About Sudeep Pharma

Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in India, the United States, and internationally. The company provides mineral salts, such as iron, calcium, sodium, zinc, copper, magnesium, manganese, potassium, picolinates, simethicone, and others;It also offers micronutrient premixes and liposomal, encapsulated ingredients, spray-dried formats, granulated ingredients, and triturated for sports nutrition, medical and clinical nutrition, infant nutrition, b...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 525
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SUDEEPPHRM

Financial Performance

In fiscal year 2026, Sudeep Pharma's revenue was 6.42 billion, an increase of 27.94% compared to the previous year's 5.02 billion. Earnings were 1.73 billion, an increase of 24.63%.

Analyst Summary

According to 2 analysts, the average rating for SUDEEPPHRM stock is "Sell." The 12-month stock price target is ₹777.50, which is a decrease of -35.48% from the latest price.

Price Target

₹777.50

(-35.48% downside)

Analyst Consensus: Sell

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error